NovoSeven in warfarin-treated patients
(2000) In Blood Coagulation and Fibrinolysis 11(Suppl 1). p.113-115- Abstract
- Haemorrhages represent a major complication of treatment with vitamin K antagonists. In cases of severe bleeding, a prompt effect on the increased International Normalized Ratio value is vital to achieve haemostasis. As conventional treatment, that is plasma or plasma-derived concentrates, carries the risk of blood-borne virus transmission, new treatments are needed. An open, multicentre pilot trial is currently under way to determine the effect of recombinant activated factor VII (rFVIIa; NovoSeven) administered to patients experiencing a bleeding episode after receiving vitamin K antagonists. When rFVIIa was given to a patient with a warfarin-induced nosebleed, it had an immediate haemostatic effect and the International Normalized Ratio... (More)
- Haemorrhages represent a major complication of treatment with vitamin K antagonists. In cases of severe bleeding, a prompt effect on the increased International Normalized Ratio value is vital to achieve haemostasis. As conventional treatment, that is plasma or plasma-derived concentrates, carries the risk of blood-borne virus transmission, new treatments are needed. An open, multicentre pilot trial is currently under way to determine the effect of recombinant activated factor VII (rFVIIa; NovoSeven) administered to patients experiencing a bleeding episode after receiving vitamin K antagonists. When rFVIIa was given to a patient with a warfarin-induced nosebleed, it had an immediate haemostatic effect and the International Normalized Ratio value virtually normalized. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1117572
- author
- Berntorp, Erik LU ; Stigendal, L ; Lethagen, Stefan LU ; Olofsson, L and Hedner, U
- organization
- publishing date
- 2000
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood Coagulation and Fibrinolysis
- volume
- 11
- issue
- Suppl 1
- pages
- 113 - 115
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- pmid:10850575
- scopus:0034080555
- ISSN
- 1473-5733
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical Coagulation Research Unit (013242510), Emergency medicine/Medicine/Surgery (013240200)
- id
- 03fe2c0f-ad77-446e-818d-8e71edebb945 (old id 1117572)
- date added to LUP
- 2016-04-01 11:49:44
- date last changed
- 2022-01-26 18:52:24
@article{03fe2c0f-ad77-446e-818d-8e71edebb945,
abstract = {{Haemorrhages represent a major complication of treatment with vitamin K antagonists. In cases of severe bleeding, a prompt effect on the increased International Normalized Ratio value is vital to achieve haemostasis. As conventional treatment, that is plasma or plasma-derived concentrates, carries the risk of blood-borne virus transmission, new treatments are needed. An open, multicentre pilot trial is currently under way to determine the effect of recombinant activated factor VII (rFVIIa; NovoSeven) administered to patients experiencing a bleeding episode after receiving vitamin K antagonists. When rFVIIa was given to a patient with a warfarin-induced nosebleed, it had an immediate haemostatic effect and the International Normalized Ratio value virtually normalized.}},
author = {{Berntorp, Erik and Stigendal, L and Lethagen, Stefan and Olofsson, L and Hedner, U}},
issn = {{1473-5733}},
language = {{eng}},
number = {{Suppl 1}},
pages = {{113--115}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Blood Coagulation and Fibrinolysis}},
title = {{NovoSeven in warfarin-treated patients}},
volume = {{11}},
year = {{2000}},
}